EWPI Emerging World Pharma Inc (CE)

Emerging World Pharma Inc. (PINKSHEETS: EWPI), strategic partner African Global Pharma (AGP), as part of an exclusive marketing and distribution agreement, will begin testing and manufacturing of generic pharmaceuticals for the Catholic Diocese of Sunyani, Ghana.

The Diocese of Sunyani will be the sole distributor for all drugs manufactured by African Global Pharma Ghana Ltd. This strategic partnership will allow priority access to Catholic Mission Hospitals in Ghana, West Africa and the rest of the African continent. The Diocese of Sunyani will also market AGP products to other private and public hospitals and pharmacies.

In addition, drugs manufactured by African Global Pharma will be marketed and sold for private and public sale and use throughout West Africa.

AFG expects to conclude all World Health Organization standards and comply with the Food and Drug board of Ghana within 30 days. Once these requirements are met testing and manufacturing of the drugs will begin immediately.

www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com